<DOC>
	<DOCNO>NCT02761486</DOCNO>
	<brief_summary>Regular use aspirin may reduce incidence colorectal cancer ( CRC ) . However , unclear mechanism aspirin exerts effect , decrease CRC risk cause side effect . Recently , imbalanced gut microbiome link inflammation CRC risk . The main hypothesis study aspirin may decrease CRC risk via target gut microbiome . The study randomize placebo-controlled double-blinded design , recruit 50 healthy subject , 50-75 year old , PRospective Evaluation SEPTin 9 ( PRESEPT ) cohort live great Twin Cities area , receive either aspirin placebo 6 week .</brief_summary>
	<brief_title>Effect Aspirin Gut Microbiome</brief_title>
	<detailed_description>The pilot study evaluate feasibility conduct large randomize trial estimate effect aspirin gut microbiome . The study recruit 50 healthy subject , 50-75 year old , PRospective Evaluation SEPTin 9 ( PRESEPT ) cohort live great Twin Cities area . The Primary Aim estimate impact 3- 6-week intake daily 325 mg aspirin composition gut microbiome use randomize placebo-controlled double-blinded design , i.e . examine change microbiome time within subject . The hypothesis aim aspirin arm versus placebo arm , gut microbiome composition shift towards low proportion pro-inflammatory , CRC-predisposing bacteria ( e.g . Fusobacteria ) high proportion anti-inflammatory , CRC-protective bacteria ( e.g . butyrate-producing bacteria ) . The Secondary Aims examine correlation aspirin-related change microbiome profile level circulate inflammatory biomarkers urine plasma . Within-individual between-arm difference microbiome composition compare 3 6 week aspirin intake . Also , microbiome composition compare 3-week 6-week wash-out period test whether period sufficient restore gut microbiome composition pre-treatment level . This study inform future crossover randomize study focus CRC preventive intervention enable clinician identify optimal candidate aspirin therapy purpose CRC prevention use accessible cheap drug .</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Healthy adult age 5075 year reside within great Twin Cities area Capable willing comply entire study protocol Able give voluntary write informed consent . Use aspirincontaining product nonsteroidal antiinflammatory drug ( NSAIDs ) ( ≥ 2 day per week regular basis ) Known hypersensitivity NSAIDs Any active cancer , history gastrointestinal cancer , chronic disease peptic ulcer , irritable bowel syndrome , inflammatory bowel disease , intestinal malabsorption syndrome gastrointestinal disorder History coagulation , bleeding , blood disorder ( e.g . Anemia ) History stroke/ Transient Ischemic Attack Acute heart disease history heart attack , atrial fibrillation , angina Diagnosis dementia Use antibiotic , antiplatelets ( e.g . clopidogrel ) , anticoagulant ( e.g . warfarin ) within last 3 month . A complete list contraindicate medication provide ( Appendix A ) Regular use laxative ( e.g . Exlax , Dulcolax , Miralax ) may affect microbiome ≥2 day week ( Appendix B ) Body mass index ( BMI ) great equal 40 less equal 17 kg/m2 screen visit Unexplained change weight ( &gt; 4.5 kg ) within past 6 month Major change eat habit within past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>aspirin</keyword>
	<keyword>gut microbiome</keyword>
	<keyword>inflammation</keyword>
	<keyword>placebo</keyword>
	<keyword>circulate biomarker</keyword>
</DOC>